Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes ...
Crescent Biopharma, Inc. (NASDAQ: CBIO) is a clinical-stage biotechnology company headquartered in Waltham, Massachusetts, dedicated to advancing the next wave of cancer treatments. The company was founded on September 19, 2024, following a merger with GlycoMimetics, and is led by CEO Joshua T. Brumm, who brings extensive experience in biotech ...Crescent Biopharma, Inc. (NASDAQ: CBIO) is a clinical-stage biotechnology company headquartered in Waltham, Massachusetts, dedicated to advancing the next wave of cancer treatments. The company was founded on September 19, 2024, following a merger with GlycoMimetics, and is led by CEO Joshua T. Brumm, who brings extensive experience in biotech leadership. With a team of 44 employees, Crescent Biopharma focuses on developing precision-engineered medicines targeting verified oncology biology.
Its lead product candidate, CR-001, is a proprietary bispecific antibody designed to simultaneously target PD-1 and VEGF pathways, offering a novel approach for solid tumors. The pipeline also includes CR-002 and CR-003, expanding its therapeutic reach. The company maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., aiming to jointly advance and commercialize oncology therapeutics, including innovative combination strategies.
Financially, Crescent Biopharma is in a development stage with no revenue, and its financial metrics reflect heavy investment in R&D (with R&D expenses significantly exceeding revenue) and negative profitability, as typical for clinical-stage biotech. As of the latest data, the company has a market cap of approximately $625 million, with a price-to-book ratio of 3.15, and a strong current ratio of 9.66, indicating ample liquidity. The company's enterprise value is around $455 million, with negative EBITDA due to operating losses.
Despite these losses, the company has a solid cash position, with cash per share of $5.62, supporting its research activities. The leadership team is seasoned, with experience in building and leading biotech companies, and the company's vision is to build a world-leading oncology company. Crescent Biopharma is actively trading on the NASDAQ Capital Market, and its stock has ranged from $8.72 to $27.41 over the past year. The company's commitment to innovation and strategic collaborations positions it as a notable player in the oncology space.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$10.8M
—
-100.0%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-153.9M
-217.3%
+2.6%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+100.0%
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
-1407.5%
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-1419.6%
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-144.5M
-364.4%
-14.0%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
-1332.1%
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
0.8%
+100.3%
+4.9%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
6.56x
+81.2%
-29.9%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
